All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@orlysgrrl's GLP-1 claims about side effects, fact-checked

Jana Marie

TikTok creator

316.5K viewsWatch on TikTok→

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @orlysgrrl actually say?

The clip is brief and decontextualized. @orlysgrrl says: "So do you not know that I have feelings or do you just not care that I have feelings?" That's the entirety of the transcript. Without the reply video from @michelle_motor_city that prompted this, we're reading tea leaves here. But the GLP-1 category tag and the emotional framing make the implied subject pretty clear: emotional blunting, mood changes, or interpersonal friction that users commonly attribute to semaglutide or tirzepatide.

This appears to be a personal expression of emotional distress, possibly related to how a relationship or support system has responded to the creator's GLP-1 experience. It is not a medical claim. It's a feeling. And feelings, it turns out, are actually a documented and underexplored dimension of GLP-1 pharmacology.

Does the science back this up?

Yes, partially, and more than the FDA's current labeling reflects. There is growing clinical interest in how GLP-1 receptor agonists affect mood, emotional processing, and interpersonal dynamics. A 2023 pharmacovigilance analysis published in eClinicalMedicine (Kose et al.) identified signals for depression and suicidal ideation in the FDA Adverse Event Reporting System for semaglutide users, though causality remains unestablished.

Separately, GLP-1 receptors are expressed in limbic brain regions including the amygdala and hippocampus, areas involved in emotional regulation. Animal studies from Kanoski et al. (2016, Neuropharmacology) showed that GLP-1 receptor activation in the brain influences reward processing and anxiety-like behavior. Human data are limited but emerging. What clinicians are seeing anecdotally, and what patients are posting about, is a flattening of emotional reactivity that some find distressing and others find stabilizing. The science does not yet explain which patients experience which outcome, or why.

What did they get wrong (or right)?

@orlysgrrl did not make a false medical claim, so there's nothing to correct on that front. What's worth naming, though, is the broader pattern this clip fits into: people on GLP-1 medications experiencing emotional shifts that their social circles don't recognize or take seriously.

That's real, and it's documented. Research on weight loss and identity disruption, including work by Pratt et al. (2023, Obesity), shows that rapid body composition changes can destabilize personal relationships and self-perception in ways that the prescribing encounter rarely addresses. The emotional experience of being on a GLP-1 drug is not just about nausea and injection schedules. It involves changes in how people relate to food, pleasure, reward, and sometimes to other people.

What's missing from this clip, not a criticism of the creator but a gap worth flagging, is any connection to whether GLP-1 pharmacology might be contributing to whatever emotional friction she's describing. That's a conversation worth having with a prescriber, not just a TikTok audience.

What should you actually know?

If you're on a GLP-1 medication and noticing mood changes, emotional blunting, or shifts in how you relate to the people around you, you're not imagining it and you're not alone. This is an underreported side effect category, and the research is still catching up to what patients have been saying for two years.

The FDA added a safety review for suicidality signals to semaglutide in 2023, though the agency's preliminary conclusion was that evidence did not confirm causality. That review is ongoing. Liraglutide has longer safety data and does not carry the same signal at comparable intensity, but all GLP-1 drugs share the same receptor mechanism in brain tissue.

If you are experiencing significant mood changes, talk to your prescriber before adjusting your dose or stopping the medication. Abrupt discontinuation of GLP-1 therapy has its own documented effects on appetite and weight rebound, and a prescriber needs to weigh those against mood symptoms case by case. This is not a reason to avoid these medications. It is a reason to take the full picture of your experience seriously and to expect your prescriber to do the same.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @orlysgrrl's GLP-1 claims about side effects, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@orlysgrrl's GLP-1 claims about side effects, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim verdict

The useful answer behind this video

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment.

FormBlends verdict

GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.
  • GLP-1 receptors are present in limbic brain regions; Kanoski et al. (2016, Neuropharmacology) showed receptor activation affects reward and anxiety-like behavior in animal models.
  • The FDA issued a safety communication in 2023 reviewing suicidality signals for semaglutide; preliminary findings did not confirm causality, but the review is ongoing.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GLP-1 receptors are present in limbic brain regions; Kanoski et al. (2016, Neuropharmacology) showed receptor activation affects reward and anxiety-like behavior in animal models.
  • The FDA issued a safety communication in 2023 reviewing suicidality signals for semaglutide; preliminary findings did not confirm causality, but the review is ongoing.
  • A 2023 eClinicalMedicine pharmacovigilance analysis (Kose et al.) identified depression and suicidal ideation signals in GLP-1 FAERS data, though these are hypothesis-generating, not conclusive.
  • Emotional blunting and mood flatness are among the most commonly reported but least clinically documented subjective side effects of semaglutide and tirzepatide.
  • Rapid body composition changes from GLP-1 therapy can disrupt personal relationships and self-identity in ways that prescribers rarely address, per Pratt et al. (2023, Obesity).
  • Patients experiencing mood changes on GLP-1 medications should not self-discontinue; abrupt cessation is associated with appetite rebound and weight regain and requires a managed clinical approach.
  • The emotional experience of GLP-1 therapy, including changes in food-related reward and interpersonal dynamics, is a legitimate clinical topic that deserves more than a brief side-effect checklist at the prescribing visit.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jana Marie · TikTok creator

316.5K views on this video

Replying to @michelle_motor_city

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jana Marie, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.